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Purpose: S-1 is an oral antineoplastic agent that contains a prodrug of 5-fluorouracil and has adverse effects on skin,
alimentary tract mucosa, and the ocular surface. We investigated the effects of S-1 on the corneal epithelium by in vivo
confocal microscopy and histopathologic analysis.
Methods: Twelve patients with eye problems related to S-1 treatment participated in the study. Twenty eyes of ten subjects
were evaluated by laser-scanning confocal microscopy. Corneal epithelial debridement as a diagnostic therapy and
histopathologic analysis were performed for five eyes of three subjects affected in the pupillary zone of the cornea.
Results: Slitlamp examination revealed a local limbal abnormality characterized by epithelial invasion toward the center
of the cornea in all 24 eyes. In vivo confocal microscopy revealed an altered structure of the corneal epithelium with
abnormal epithelial cells and inflammation. One of five specimens subjected to cytologic diagnosis showed moderate
dysplasia. Hematoxylin and eosin staining showed that each abnormal epithelial sheet lacked the stratified structure of
the normal corneal epithelium. Immunofluorescence analysis revealed the presence of cells positive for one, both, or
neither of cytokeratins 12 and 4 in each lesion.
Conclusions: S-1 can induce ocular mucositis with dysplasia, likely affecting cellular functions, including differentiation,
of the corneal epithelium. In vivo confocal microscopy allowed the noninvasive detection of cellular changes in the cornea
as an adverse effect of S-1 administration.
Oral and gastrointestinal mucositis is a frequent adverse
effect  of  chemotherapy  or  radiotherapy  for  cancer.  5-
Fluorouracil (5-FU) is a common chemotherapeutic agent, the
administration of which is associated with severe mucositis
[1].  S-1  is  an  oral  antineoplastic  drug  that  is  an  active
combination of tegafur (a prodrug of 5-FU), gimeracil, and
oteracil [2]. It is more active and less toxic than intravenous
5-FU, being associated with fewer gastrointestinal adverse
effects. It is possible to achieve a high concentration of 5-FU
in patients for a longer time with S-1, although adverse effects
are  still  induced  in  sensitive  organs  and  tissues  [2,3].
Myelosuppression, skin rash, anorexia, nausea, vomiting, and
fatigue have been reported as major adverse effects of S-1
therapy [2,4], with the alimentary tract mucosa and skin, both
of which are multilayered epithelia consisting of cells with
high metabolic and turnover rates, being especially sensitive
to drug toxicity [4,5].
The ocular surface, consisting of the cornea, conjunctiva,
lacrimal system, and eyelid, is also lined with a multilayered
mucosal epithelium that protects the underlying connective
tissue  (Figure  1).  5-FU  can  be  detected  in  tears  after  its
intravenous administration [6,7] and 5-FU in tear fluid is
thought to induce ocular surface and lacrimal complications.
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Both tearing and blurred vision have been reported with a
prevalence of >10% in patients treated with 5-FU [8]. Tearing,
conjunctivitis, keratitis, eye pain, and visual disturbance are
listed as ophthalmic adverse effects of S-1 administration on
the package insert in Japan. As far as we are aware, however,
the incidence and pathology of ocular surface complications
in patients treated with S-1 have not been fully characterized,
with a histopathologic investigation of S-1–induced corneal
disorders not having been performed.
The development of an in vivo laser confocal microscope
with  an  attachment  for  the  cornea  (Heidelberg  Retina
Tomograph II–Rostock Cornea Module, or HRTII-RCM®;
Heidelberg Engineering, Heidelberg, Germany) has yielded
new insights into ocular surface disorders by providing high-
resolution images of cells at the ocular surface (Figure 1). In
addition to ocular surface cells [9-12], the development of
confocal optics has allowed the oral mucosa, tongue, and teeth
to be examined layer by layer at the cellular level [11,13].
The purpose of the present study was to characterize
specific pathologic features of the cornea in patients with S-1-
induced  corneal  disorders  with  the  use  of  in  vivo  laser
confocal microscopy in order to provide an insight into disease
pathogenesis.
METHODS
Subjects: We undertook an evaluation of 12 patients with
corneal  disorders  associated  with  S-1  (TS-1®;  Taiho
Pharmaceutical, Tokyo, Japan) administration at Yamaguchi
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2896University Hospital, Ube, Japan. All patients were referred to
our hospital by their local ophthalmologists for diagnosis or
treatment of their corneal epithelial disorders. All patients
received  S-1  as  adjuvant  chemotherapy.  Sex,  age,  visual
acuity, ophthalmic symptoms, and general symptoms of the
patients  as  well  as  their  corneal  findings  by  slitlamp
biomicroscopy  and  in  vivo  confocal  microscopy  were
recorded. The study was approved by the Institutional Review
Board of Yamaguchi University Hospital, and all patients
provided informed consent to participate in the study. The
protocol  adhered  to  the  principles  of  the  Declaration  of
Helsinki.
Figure 1. In vivo confocal microscopy of the cornea and the limbus in a normal eye with the an in vivo laser confocal microscope with an
attachment for the cornea (Heidelberg Retina Tomograph II–Rostock Cornea Module, or HRTII-RCM®; Heidelberg Engineering, Heidelberg,
Germany). Panels A through F represent areas of 400×400 µm corresponding to the superficial epithelial cell layer, wing cell layer, basal cell
layer, Bowman’s layer, mid stroma, and endothelium, respectively. The approximate levels of the sections are indicated in the hematoxylin
and eosin-stained histologic specimen. Panels G and H show the limbus at the border between the cornea and conjunctiva and the limbal
palisades of Vogt, respectively. The peripheral cornea often retains melanocytes in the basal epithelial layer (inset in G).
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2897In  vivo  laser  confocal  microscopy:  In  vivo  confocal
microscopy  was  performed  with  an  HRTII-RCM  system
(Heidelberg Engineering) as previously described [14]. In
summary,  a  drop  of  local  anesthetic  (0.4%  benoxinate
hydrochloride; Santen, Osaka, Japan) was instilled into the
lower  fornix  of  each  eye,  and  a  drop  of  polymer  gel
(Viscotears; CIBA Vision, Atlanta, GA) was applied to the
microscope  probe  to  allow  for  optical  coupling  of  the
microscope objective lens to the cornea. Corneal lesions were
scanned by alternating vertical and horizontal movement from
the center to the limbus. Several confocal microscopic images
of tangential optical sections of the superficial, wing, and
basal  cell  layers  of  the  corneal  epithelium,  stroma,  and
endothelium were obtained for each eye. Oblique sections
were also obtained when abnormal findings are observed and
to confirm their orientation. No complications of examination
with the HRTII-RCM system were noted.
Histopathologic analysis: Corneal epithelial debridement was
performed as diagnostic therapy for the five eyes of three
subjects that were affected in the pupillary zone of the cornea.
Frozen sections of the lesion specimens were examined by
Hematoxylin and Eosin (HE; Merck, Darmstadt, Germany)
staining and immunofluorescence staining for cytokeratins.
For double immunofluorescence staining of cytokeratin 12
(K12,  which  is  specific  for  corneal  epithelial  cells)  and
cytokeratin  4  (K4,  which  shows  a  high  specificity  for
conjunctival  epithelial  cells),  sections  were  incubated
consecutively with rabbit polyclonal antibodies to mouse K12
(University of Cincinnati, Cincinnati, OH and Wakayama
Medical University, Wakayama, Japan), Alexa Fluor 488–
conjugated  antibodies  to  rabbit  immunoglobulin  G
(Molecular  Probes,  Eugene,  OR),  mouse  monoclonal
antibodies to K4 (Sigma, St. Louis, MO), and Alexa Fluor
555–conjugated  antibodies  to  mouse  immunoglobulin  G
(Molecular  Probes).  Nuclei  were  stained  with  4′,6-
diamidino-2-phenylindole (Molecular Probes, Eugene, OR).
RESULTS
Clinical and slitlamp biomicroscopy findings: The clinical
characteristics  of  the  12  patients  with  bilateral  corneal
disorders are shown in Table 1. The patients included seven
men  and  five  women,  with  an  overall  mean±standard
deviation (SD) age of 64.3±7.6 years (range, 52–78 years). No
history of ocular surface disorders was revealed for any of the
patients in individual interviews. All patients reported some
type of ocular discomfort. Subjective ophthalmic symptoms
included  visual  disturbance,  tearing,  and  foreign  body
sensation in six, eight, and eight patients, respectively. Eight
patients had skin problems, including increased pigmentation
in seven individuals, and nail abnormalities were apparent in
four  patients.  Subjective  ophthalmic  symptoms  were  first
noticed  from  1.5  to  36  months  after  the  onset  of  S-1
administration, with an overall mean±SD of 7.9±10.2 months.
Corneal epithelial disorders were detected in both eyes of
all patients by slitlamp examination, with their appearance
being enhanced by fluorescein staining. Images of two typical
staining patterns revealing sheet-like or superficial punctate
keratopathy (SPK)–like lesions are shown in Figure 2. A hazy
epithelial lesion (sheet-like lesion) extending into the central
region of the cornea from the upper and lower limbus was
apparent in eight of the 24 eyes, whereas a diffuse, rugged,
surface  lesion  positive  for  fluorescein  staining  (SPK-like
lesion) was detected in the remaining 16 eyes. Palisades of
Vogt  (POV),  a  limbal  feature  at  the  border  with  the
conjunctiva that is associated with the presence of corneal
epithelial stem cells, are readily detected in normal eyes by
slitlamp microscopy [15]. However, they were completely
absent in 15 of the 24 eyes and were defective in the remaining
nine eyes of the study patients.
In  vivo  laser  confocal  microscopy:  Abnormalities  of  the
cornea detected in the study patients by in vivo laser confocal
microscopy included: (1) cellular defects or turbulence of
superficial  epithelial  cells;  (2)  disruption  of  the  layered
structure of the epithelium; (3) infiltration of inflammatory
cells in the basal cell layer of the epithelium or in the shallow
stroma; (4) absence or a reduced number of subepithelial
nerves; (5) hyper-reflective granular structures at the center
of  the  epithelial  basal  cell  layer;  and  (6)  changes  in  the
structure of palisades at the limbus (Figure 2, Figure 3, and
Table 2). None of these findings were apparent in normal eyes.
All 20 eyes of the ten study patients examined exhibited
corneal  epithelial  disorders,  including  cellular  defects  or
turbulence of superficial epithelial cells as well as disruption
of the layered structure of the epithelium. Such disorders were
thus apparent for both the sheet-like and SPK-like lesions
revealed by slitlamp examination. A high density of dendritic
or  spherical  infiltrated  cells,  likely  including  Langerhans
cells,  macrophages,  monocytes,  and  neutrophils,  was  also
observed in the epithelial basal cell layer or the shallow stroma
in 17 of the 20 eyes examined. Many activated keratocytes,
characterized by a spherical nucleus and reflective cytoplasm,
were detected in the anterior stroma of the 17 eyes with a
partial or complete loss of subepithelial nerve fibers. The
posterior stroma and endothelium appeared normal in all 20
eyes. Hyper-reflective granular structures corresponding to
melanocytes are usually observed only in the basal cell layer
of the epithelium at the limbus in the normal cornea. Such
structures were detected in the central region of the cornea in
12 eyes of the study patients; patients 3, 7, and 9, all of whom
did not show an increase in skin pigmentation, did not exhibit
infiltration  of  melanocytes  at  the  central  cornea.  Palisade
structures in the limbal area, likely corresponding to POV,
were detected in 13 eyes, even though slitlamp examination
failed to detect POV in most of these eyes. However, these
structures were defective in all 13 of these eyes and were not
detected in the remaining seven eyes examined.
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2899Histopathologic analysis: Frozen sections of the lesions of
five eyes of three study patients were examined by HE staining
and immunofluorescence staining for cytokeratins (Figure 4).
HE  staining  revealed  that  each  abnormal  epithelial  sheet
lacked the well-organized stratified structure of the normal
corneal  epithelium  (Figure  4A).  The  cells  of  each  lesion
contained nuclei that were irregular in size and shape as well
as a vacuolated cytoplasm. The localization of the atypical
cells revealed by HE staining appeared to correspond to the
localization of the abnormal cells observed with the HRTII-
RCM system. Cytological diagnosis of the five specimens by
a pathologist yielded one case of moderate dysplasia and four
cases of mild dysplasia.
Immunofluorescence  staining  for  both  K12  and  K4
revealed the presence of four types of cells in each lesion:
those positive for one, both, or neither of these cytokeratins
(Figure 4A). The specimen from the right eye of patient 1,
which was classified as moderate dysplasia, exhibited double-
positive (K12 and K4) cells in the superficial cell layer, an
isolated K4-positive cell in the wing cell layer, and double-
negative cells in the wing and basal cell layers. In the left eye
of  patient  2,  epithelial  cells  expressing  K4  were  present
sporadically  in  the  superficial  and  wing  cell  layers.  Cells
lacking both K12 and K4 were observed in all layers of the
epithelium in both eyes of patient 2 and the right eye of patient
3.
Progress of the cases: In 11 of the 12 patients, administration
of S-1 was terminated with or without instigation of therapy
with  other  antineoplastic  drugs.  The  corneal  epithelial
disorders of both eyes in nine of these 11 patients healed
completely after discontinuation of S-1 treatment, whereas
those of both eyes of the remaining two patients were only
slightly ameliorated. For the seven of these 11 patients who
experienced  tearing,  canalicular  or  nasolacrimal  duct
obstruction was ameliorated in four patients but not in the
remaining  three  patients  after  discontinuation  of  S-1
administration.
Figure 2. Ocular mucositis revealed by slitlamp and in vivo confocal microscopy. Slitlamp microscopy (left panels) revealed corneal epithelial
abnormalities characterized by two patterns of turbulence (sheet-like or superficial punctate keratopathy-like (SPK-like) lesions) that were
highlighted by fluorescein staining. Confocal microscopy (right panels) revealed nonuniformity in size and intensity of superficial epithelial
cells (A), cellular defects in the superficial cell layer (B), atypical arrangement of the multilayered structure of the epithelium (C), and poorly
defined Palisades of Vogt (POV; D).
Molecular Vision 2009; 15:2896-2904 <http://www.molvis.org/molvis/v15/a306> © 2009 Molecular Vision
2900DISCUSSION
As  far  as  we  are  aware,  our  study  provides  the  first
demonstration of S-1-induced ocular mucositis. Our results
suggest  that  this  corneal  epithelial  disorder  is  related  to
dysplasia  in  S-1-treated  patients.  We  noninvasively
characterized the pathological features of the lesions with the
use of in vivo laser confocal microscopy.
The pathobiology of mucositis had been attributed to
direct epithelial injury inflicted over a long period of time. The
recent  development  of  an  animal  model  of  mucositis  [5],
however, has indicated that the pathobiology is more complex
and  involves  all  components  of  the  mucosa,  including
connective  tissue  as  well  as  the  epithelium  [16].  At  the
molecular  level  both  pro-inflammatory  cytokines  and
transcription factors are now implicated in the development
of mucositis [5]. However, the precise mechanism underlying
the development of 5-FU-induced mucositis, especially in
humans, remains to be fully determined.
Ophthalmic adverse effects of intravenous 5-FU therapy,
such as tearing, eye discharge, and canalicular stenosis, have
been  reported  [6,17,18].  However,  S-1-induced  corneal
disorders appear to be more severe than those associated with
other oral 5-FU prodrugs or intravenous 5-FU administration
[19]. Given that high concentrations of 5-FU can be achieved
for a longer time by administration of S-1, it is likely that
adverse effects at the ocular surface are induced by a high
concentration of 5-FU in tear fluid or in tissue that results from
diffusion of S-1-derived 5-FU from the limbal network of
vessels.  Further  investigation  of  the  relation  between  the
severity of corneal disorders and the concentration of 5-FU in
tear fluid is thus warranted.
Among the pathological characteristics of S-1-induced
ocular mucositis revealed by in vivo confocal microscopy in
the  present  study,  the  irregularity  of  superficial  corneal
epithelial cell alignment is suggestive of the active migration
of  epithelial  cells  to  cover  epithelial  defects,  whereas  the
abnormality  in  the  multilayered  structure  of  the  corneal
epithelium  likely  also  reflects  such  defects  or  incomplete
epithelial cell proliferation and differentiation. The toxicity of
5-FU  in  mouse  intestine  has  been  ascribed  to  both  the
Figure 3. Inflammatory changes in ocular mucositis revealed by in vivo confocal microscopy. In vivo confocal microscopy revealed a high
density of dendritic and spherical cells, likely including Langerhans cells, macrophages, monocytes, and neutrophils, in the epithelial basal
cell layer (A, B, D) as well as many activated keratocytes in the anterior stroma (C) and a reduced number of subepithelial nerve fibers (F).
Fibrosis (arrows) with a circular pattern of degradation of Bowman’s layer was observed in a case that subsequently showed only minor
improvement after discontinuation of S-1 administration (E).
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2901induction  of  apoptosis  and  inhibition  of  cell  proliferation
[20], with these effects leading to reduced cellularity in both
intestinal  crypts  and  villi.  POV  at  the  limbus  have  a
histological structure similar to that of intestinal crypts. S-1
administration was found to result in a reduction in cellularity
of POV, as observed by both slitlamp and in vivo confocal
microscopy in the present study.
The  complete  or  partial  loss  of  subepithelial  nerves
observed in the S-1-treated patients in the present study is
indicative of nerve destruction or damage associated with an
epithelial disorder and inflammation [14,21]. The infiltration
of inflammatory cells in the epithelium and the presence of
activated keratocytes, which are characterized by reflective
nuclei and visible cytoplasmic processes [22], in the shallow
stroma of the patients are also indicative of an inflammatory
response induced by 5-FU. Cyclooxygenase-2 is upregulated
and initiates an inflammatory cascade resulting in activation
of matrix metalloproteinases and further tissue damage in
cartilage, one of the avascular tissues, such as the cornea
[23]. Persistence of inflammation would be expected to result
in the development of sight-threatening, irreversible, corneal
opacity  given  that  activated  keratocytes  produce  matrix
metalloproteinases and contribute to haze induction [22,24].
Corneal epithelial dysplasia is a rare condition that likely
arises at the limbus and spreads in a relatively flat manner over
the cornea rather than remaining restricted to the limbus or
extending into the conjunctiva. The cells of the lesion are
atypical in size and shape and they manifest a slight increase
in  the  nucleus-to-cytoplasm  ratio,  mitotic  figures,  and
disturbance  of  maturation  and  polarity  [25-27].  Epithelial
cells express specific cytokeratins. All corneal epithelial cells
thus express K12, and all conjunctival epithelial cells express
K4 [28]. Our in vivo confocal microscopic images of the
corneal epithelium showed abnormal cells that appeared to
correspond to those detected by HE staining of each excised
lesion. Immunofluorescence staining revealed four different
phenotypes of cells in the excised corneal epithelium of S-1-
treated individuals: those positive for one, both, or neither of
K12  and  K4.  The  double-positive  cells  likely  represent
conjunctival epithelial cells that invaded the cornea via the
limbus and adopted characteristics of corneal epithelial cells
(corneal epithelial metaplasia). The cells lacking both K12
and K4 likely reflect either undifferentiated cells or epithelial
cells  that  had  not  achieved  tissue-specific  cytokeratin
expression. The limbus is thought to contain corneal epithelial
stem cells [15]. The corneal epithelial disorders persisted in
two patients of the present study after discontinuation of S-1
administration, suggesting that corneal epithelial stem cells
may also have been affected by S-1 administration in these
individuals. Anticancer drugs have previously been shown to
alter the expression of cell type-specific cytokeratins [29], and
inflammation may affect the expression of junctional proteins
in corneal epithelial cells [30]. S-1 thus likely affects the
function  of  corneal  epithelial  cells,  possibly altering  their
differentiation.
The drug 5-FU and its oral prodrugs, such as S-1, induce
the development of pigmented skin lesions [31,32]. We also
observed atypical proliferation of melanocytes in the basal
cell layer of the corneal epithelium in patients who manifested
such skin lesions. The migration of these cells from their
normal location at the limbus to the central cornea may be
promoted by a deficiency of corneal epithelial cells resulting
from the antiproliferative effect of S-1.
Some patients in the present study developed irreversible
changes  of  the  corneal  epithelium  and  canalicular  or
nasolacrimal  duct  in  spite  of  discontinuation  of  S-1
administration. These findings suggest that it is important to
detect the adverse effects of S-1 early in order to prevent the
development of such irreversible changes and progression of
ocular surface disorders. Good vision depends on corneal
transparency  and  smoothness,  and  it  is  important  for
maintenance of quality of life in individuals with tumors.
In conclusion, we have described for the first time the
development of ocular mucositis in patients treated with S-1.
In  vivo  confocal  microscopy  revealed  that  the  corneal
disorders  of  S-1-treated  patients  were  characterized  by
disruption  of  the  normal  layered  structure  of  the  corneal
epithelium in association with inflammation. In vivo confocal
TABLE 2. SUMMARY OF IN VIVO CONFOCAL MICROSCOPIC FINDINGS IN PATIENTS WITH S-1–INDUCED OCULAR MUCOSITIS.
Findings (20 eyes)
Presence
  (eyes)
Absence
(eyes)
Frequency
      (%)
Cellular defect or turbulence of superficial epithelial cells 20 0 100
Disruption of layered structure of the epithelium 20 0 100
Infiltration of inflammatory cells in the epithelial basal cell layer or
the shallow stroma
Severe: 4 Moderate: 13 3 85
Partial or complete loss of subepithelial nerves Complete: 14 Partial: 3 3 85
Hyperreflective granular structures at the center of the epithelial basal
cell layer
12 8 60
Changes in the structure of palisades at the limbus Disappearance : 7
Disruption: 13
0 100
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2902microscopy may thus prove useful as a noninvasive means to
elucidate  the  pathogenesis  of  adverse  effects  of  S-1.  Its
application to the early detection of adverse effects of S-1 at
the ocular surface might also inform intervention to prevent
progression of such effects not only at the ocular surface but
also in other tissues.
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